Compare Quest Diagnostics Inc (DGX) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Hims and Hers Health Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Hims and Hers Health Inc trades at $29.92 (market cap $7.12B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× Hims and Hers Health Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| DGX | HIMS | |
|---|---|---|
Market Cap | $26.21B | $7.12B |
Sector | Health | Health |
52-Week High | $238.50 | $62.76 |
52-Week Low | $173.49 | $14.52 |
Enterprise Value | $31.97B | $7.82B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
HIMS stock trades at $29.97, down 5.67% amid mixed Q2 2026 results. Revenue growth remains strong with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a net loss. Technical indicators are neutral to bearish, with support near $29. Recent news highlights an FTC investigation and class-action lawsuits adding uncertainty.
The outlook is cautious. Growth prospects from AI and global expansion are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33 price target, suggesting limited near-term upside amid execution and profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
